NN-DNJ;Nonyl-DNJ

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: NN-DNJ;Nonyl-DNJ
• 英文别名: 2-(hydroxymethyl)-1-nonylpiperidine-3,4,5-triol
• 化学式: C₁₅H₃₁NO₄
• 分子量: 289.41
• InChiKey: FTSCEGKYKXESFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  84.2
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• PHARMACEUTICALLY ACTIVE PIPERIDINE DERIVATIVES
  申请人：BUTTERS Terence D.

  公开号：US20140303208A1

  公开（公告）日：2014-10-09

  Compounds of formula (I): wherein R represents various substituent groups, are useful as inhibitors of glucosylceramide synthase.

  式(I)的化合物：其中R代表各种取代基团，可用作葡糖酰胺合成酶的抑制剂。
• Treatment of Zika virus infections using alpha-glucosidase inhibitors
  申请人：FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC.

  公开号：US10328061B2

  公开（公告）日：2019-06-25

  The present invention concerns the use of castanospermine or other alpha-glucosidase inhibitors for the treatment or prevention of Zika virus infections. Aspects of the invention include methods for treating or preventing Zika virus infection by administering an alpha-glucosidase inhibitor (e.g., an alpha-glucosidase I inhibitor) to a subject in need thereof; methods for inhibiting a Zika virus infection in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Zika virus infection.

  本发明涉及使用蓖麻毒素或其他α-葡萄糖苷酶抑制剂治疗或预防寨卡病毒感染。本发明的各个方面包括通过向有需要的受试者施用α-葡萄糖苷酶抑制剂（如α-葡萄糖苷酶I抑制剂）来治疗或预防寨卡病毒感染的方法；抑制体外或体内细胞中寨卡病毒感染的方法；药物组合物；包装剂型；以及治疗或预防寨卡病毒感染的试剂盒。
• Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
  申请人：FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC.

  公开号：US11369592B2

  公开（公告）日：2022-06-28

  The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.

  本发明涉及使用α-葡萄糖苷酶糖蛋白加工抑制剂治疗或预防人类冠状病毒感染，如SARS-CoV-2或SARS-CoV-2变体感染。本发明的各个方面包括通过向人类受试者施用α-葡萄糖苷酶糖蛋白加工抑制剂，如蓖麻毒素或其药学上可接受的盐、衍生物或原药，治疗或预防冠状病毒感染或其症状的方法；在体外或体内抑制人体细胞中人冠状病毒感染的方法；药物组合物；包装剂型；以及治疗或预防人冠状病毒感染的试剂盒。
• TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE GLYCOPROTEIN PROCESSING INHIBITORS
  申请人：Florida State University Research Foundation, Inc.

  公开号：EP4106752A2

  公开（公告）日：2022-12-28
• SUBSTRATE REDUCTION THERAPY
  申请人：Platt Mary Frances

  公开号：US20100204162A1

  公开（公告）日：2010-08-12

  The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.